The pharmaceutical industry is a multi-billion-dollar market for a reason – people need therapeutic relief from a multitude of conditions. However, that need does not always translate to patients getting the most effective dosing from their medications. Lexaria Bioscience (OTCMKTS: LXRP) is focused on fixing that problem. 

The company's drug delivery platform, DehydraTECH™, is a potentially disruptive drug delivery technology that can extend seamlessly through the pharmaceutical sector by taking existing orally-administered therapies and improving the way they are detected and absorbed by the body. Lexaria is looking to monetize that opportunity by working with already approved drugs with the goal of making them better.

That's important on several fronts. First, it helps to facilitate substantial manufacturing opportunities that position Lexaria to integrate its next-gen dehydration technology for existing drugs without facing lengthy and cost-prohibitive FDA oversight. Second, by focusing on already marketed products, the company is positioned to address an enormous universe of marketed drug product opportunities that can be made better. Third, because the technology may have the potential to extend patent protection for billion-dollar drug franchises, clients will likely be attracted to increasing their power brands' longevity. 

The most important component to the mix is that the technology works. Testing shows a unique ability for DehydraTECH™ to increase drug effectiveness at lower dosages. The therapeutic benefit and time to relief are also appreciably better. Moreover, proof of concept studies, supported by data from already licensed and marketed products, has reinvigorated interest from the nicotine, pharmaceutical-grade CBD, and disease treatment sectors.